CCM
NKTR icon

Cupps Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Cupps Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$2.33M Sell
9,027
-2,143
-19% -$552K 1.01% 24
2016
Q2 		$2.38M Sell
11,170
-8,609
-44% -$1.92M 0.62% 59
2016
Q1 		$4.08M Sell
19,779
-3,355
-15% -$644K 0.78% 48
2015
Q4 		$5.85M Buy
+23,134
New +$4.76M 0.82% 48

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

Cupps Capital Management's NKTR Position: Q3 2016 in Review

Cupps Capital Management reduced its Nektar Therapeutics (NKTR) stake by 19% in Q3 2016, selling an estimated $552K and leaving 9,027 shares worth $2.33M. The position accounts for 1.01% of the portfolio, ranked #24.

Cupps Capital Management first reported a position in NKTR in Q4 2015 and has held it in 4 quarters since. The position peaked at $5.85M in Q4 2015. 194 funds tracked by Wall St. Rank hold NKTR as of Q3 2016.

  • Cupps Capital Management held 9,027 shares of Nektar Therapeutics worth $2.33M as of Q3 2016.
  • Cupps Capital Management sold 2,143 Nektar Therapeutics shares in Q3 2016, an estimated $552K.
  • Nektar Therapeutics made up 1.01% of Cupps Capital Management's portfolio in Q3 2016, its #24 holding.
  • Cupps Capital Management first reported a position in Nektar Therapeutics in Q4 2015 and has held it in 4 quarters since.
  • Cupps Capital Management's Nektar Therapeutics position peaked at $5.85M in Q4 2015.
  • 194 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2016.

Based on Cupps Capital Management's 13F filing for Q3 2016, filed 11 Oct 2016.